Early genetic markers for blood cancers

In August 2026, researchers at the Wellcome Sanger Institute and partner institutions reported that DNA alterations can reveal the risk of myeloproliferative neoplasms (MPNs) years before clinical symptoms appear. By analysing hundreds of blood samples and thousands of test results, they constructed genetic “family trees” that tracked cell‑lineage evolution, showing that stable disease correlates with few new mutations while progression is marked by additional changes. The findings, published in *Cancer Discovery* and presented at the AACR conference, underscore the potential for earlier diagnosis, more precise monitoring and targeted treatment of chronic blood‑forming tumours that affect tens of thousands in the United Kingdom.

A separate international investigation identified a key genetic change that drives myeloid leukemia in children with Down syndrome, linking the disease to transient abnormal myelopoiesis present in some newborns. This discovery could enable earlier detection and risk‑stratified monitoring of high‑risk children, paving the way for less aggressive, biology‑driven therapies. Together, the studies highlight a growing focus on genetic markers as tools for pre‑symptomatic identification and intervention in diverse blood‑cancer contexts.